VYNE Therapeutics Inc.

VYNE

$0.558

Name : VYNE Therapeutics Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $18,587,138.00

EPSttm : -0.79

VYNE Therapeutics Inc.

$0.558

0.22%

$0.0012

Float Short %

1.77

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.01

EPS Last/This Y

0.04

EPS This/Next Y

-0.21

Price

0.56

Target Price

Analyst Recom

2.33

Performance Q

53.83

Relative Volume

0.04

Beta

2.02

Ticker: VYNE

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	VYNE	0.5676	N/A	N/A	0
2026-01-14	VYNE	0.5666	N/A	N/A	0
2026-01-15	VYNE	0.5777	N/A	N/A	0
2026-01-16	VYNE	0.5668	N/A	N/A	0
2026-01-20	VYNE	0.5741	N/A	N/A	0
2026-01-21	VYNE	0.5819	N/A	N/A	0
2026-01-22	VYNE	0.586	N/A	N/A	0
2026-01-23	VYNE	0.5802	N/A	N/A	0
2026-01-26	VYNE	0.5748	N/A	N/A	0
2026-01-27	VYNE	0.57	N/A	N/A	0
2026-01-28	VYNE	0.5646	N/A	N/A	0
2026-01-29	VYNE	0.5671	N/A	N/A	0
2026-01-30	VYNE	0.5631	N/A	N/A	0
2026-02-02	VYNE	0.573	N/A	N/A	0
2026-02-03	VYNE	0.5672	N/A	N/A	0
2026-02-04	VYNE	0.5804	N/A	N/A	0
2026-02-05	VYNE	0.5623	N/A	N/A	0
2026-02-06	VYNE	0.5631	N/A	N/A	0
2026-02-09	VYNE	0.5571	N/A	N/A	0
2026-02-10	VYNE	0.5571	N/A	N/A	0
2026-02-11	VYNE	0.5572	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	VYNE	0.57	-	-	-0.89
2026-01-14	VYNE	0.57	-	-	-0.89
2026-01-15	VYNE	0.57	-	-	-0.89
2026-01-16	VYNE	0.57	-	-	-0.89
2026-01-20	VYNE	0.57	-	-	-0.89
2026-01-21	VYNE	0.58	-	-	-0.89
2026-01-22	VYNE	0.58	-	-	-0.89
2026-01-23	VYNE	0.58	-	-	-0.89
2026-01-26	VYNE	0.58	-	-	-0.89
2026-01-27	VYNE	0.57	-	-	-0.89
2026-01-28	VYNE	0.57	-	-	-0.89
2026-01-29	VYNE	0.57	-	-	-0.89
2026-01-30	VYNE	0.56	-	-	-0.89
2026-02-02	VYNE	0.57	-	-	-0.89
2026-02-03	VYNE	0.58	-	-	-0.89
2026-02-04	VYNE	0.58	-	-	-0.89
2026-02-05	VYNE	0.56	-	-	-0.89
2026-02-06	VYNE	0.56	-	-	-0.89
2026-02-09	VYNE	0.56	-	-	-0.89
2026-02-10	VYNE	0.56	-	-	-0.89
2026-02-11	VYNE	0.56	-	-	-0.89
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	VYNE	0.00	-12.57	5.49
2026-01-14	VYNE	0.00	-12.57	5.49
2026-01-15	VYNE	0.00	-12.57	5.49
2026-01-16	VYNE	0.00	-12.57	5.49
2026-01-20	VYNE	0.00	-12.57	5.49
2026-01-21	VYNE	0.00	-12.57	5.49
2026-01-22	VYNE	0.00	-12.57	5.49
2026-01-23	VYNE	0.00	-12.57	5.49
2026-01-26	VYNE	0.00	-12.49	5.49
2026-01-27	VYNE	0.00	-12.49	5.49
2026-01-28	VYNE	0.00	-12.49	2.45
2026-01-29	VYNE	0.00	-12.49	2.45
2026-01-30	VYNE	0.00	-12.49	2.45
2026-02-02	VYNE	0.00	-12.50	2.45
2026-02-03	VYNE	0.00	-12.50	2.45
2026-02-04	VYNE	0.00	-12.50	2.45
2026-02-05	VYNE	0.00	-12.50	2.45
2026-02-06	VYNE	0.00	-12.50	2.45
2026-02-09	VYNE	0.00	-11.14	2.45
2026-02-10	VYNE	0.00	-11.14	2.45
2026-02-11	VYNE	0.00	-11.14	1.77
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.23

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

Institutional Transactions

-11.14

Beta

2.02

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.7

Max Drawdown 5-Year %

-99.9

Target Price

P/E

Forward P/E

PEG

P/S

35.75

P/B

0.55

P/Free Cash Flow

EPS

-0.79

Average EPS Est. Cur. Y

-0.89

EPS Next Y. (Est.)

-1.1

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6425.19

Relative Volume

0.04

Return on Equity vs Sector %

-132.8

Return on Equity vs Industry %

-116.4

EPS 1 7Days Diff

-0.9

EPS 1 30Days Diff

-0.89

EBIT Estimation

VYNE Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 13

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

stock quote shares VYNE – VYNE Therapeutics Inc. Stock Price stock today

news today VYNE – VYNE Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VYNE – VYNE Therapeutics Inc. yahoo finance google finance

stock history VYNE – VYNE Therapeutics Inc. invest stock market

stock prices VYNE premarket after hours

ticker VYNE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VYNE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y